David Banas-Conejero
Overview
Explore the profile of David Banas-Conejero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez-Moragon E, Pinedo C, Puente L, Puente-Maestu L, Munoz Esquerre M, Munoz-Esquerre M, et al.
J Asthma
. 2025 Feb;
:1-5.
PMID: 39918279
Objective: Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness,...
2.
Gonzalez-Barcala F, Bobolea I, Dominguez-Ortega J, Banas-Conejero D, Antelo-Cea E, Martinez-Moragon E, et al.
ERJ Open Res
. 2025 Feb;
11(1).
PMID: 39902267
Introduction: Severe asthma involves a persistent inflammation of the airways that is associated with a greater risk of exacerbations. Exacerbations are associated with a higher lung function decline over time....
3.
Bakakos P, Alobid I, Constantinidis J, Hellings P, Pfaar O, Taille C, et al.
J Allergy Clin Immunol Glob
. 2024 Nov;
4(1):100343.
PMID: 39554605
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma (SA) are 2 frequently coexisting conditions that are, in most cases, associated with eosinophilic inflammation. The concurrence of both diseases...
4.
Del Pozo V, Bobolea I, Rial M, Espigol-Frigole G, Solans Laque R, Hernandez-Rivas J, et al.
Front Immunol
. 2024 Jan;
14:1310211.
PMID: 38250075
Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated...
5.
Dominguez-Ortega J, Laorden D, Vilchez-Sanchez F, Banas-Conejero D, Quirce S
J Asthma
. 2023 Jul;
61(1):39-47.
PMID: 37503953
Objective: To define the cost-effectiveness and health resource use of mepolizumab in a cohort of patients with severe eosinophilic asthma in real-life conditions in Spain. Methods: This was an observational,...
6.
Domingo C, Sogo A, Casado E, Martinez-Moragon E, Blanco-Aparicio M, Carrillo T, et al.
Front Pharmacol
. 2023 May;
14:1183156.
PMID: 37229249
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the...
7.
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, et al.
Front Immunol
. 2023 May;
14:1150162.
PMID: 37122713
Introduction: Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This analysis used data from the REDES study to assess the proportion of...